NRAS and ovarian cancer: 58 patients were enrolled and received Alp (80–270 mg once daily) with MEK162 (30 or 45 mg twice-daily dose) in 28 day cycle. DLTs were observed in 9 patients (19%).The MTD of this combination was defined at Alp 200 mg once daily + MEK162 45 mg twice daily doses. Out of 4 ovarian cancer patients with KRAS-mutation, 3 had PRs. PR was also confirmed in 1 patient with NRAS-mutant melanoma and 1 patient with KRAS-mutant endometrial cancer (unconfirmed). SD lasting over 6 weeks was reported as best response for 18 patients (31%).